Korean pharmaceutical and biotech companies are heading to the American Diabetes Association (ADA) 2026 Scientific Sessions in New Orleans with obesity and metabolic disease pipelines that reflect the industry's shift beyond simple weight loss toward muscle preservation, management of metabolic comorbidities, and more convenient dosing. For overseas aesthetic buyers and distributors, this signals a growing pipeline of injectable and oral GLP-1 therapies that could reshape the supply chain for obesity treatments, offering opportunities for sourcing long-acting formulations and muscle-preserving agents.
Key players and pipeline highlights
Hanmi Pharmaceutical will present eight studies on two candidates: LA-UCN2 (HM17321), a long-acting urocortin 2 analog targeting CRFR2 for muscle preservation and metabolic health, and LA-MSTN (HM500197), a peptide-based myostatin inhibitor to offset muscle loss during weight reduction. MetaVia, a Dong-A ST affiliate, will present three late-breaking posters on DA-1726, a once-weekly oxyntomodulin analog, and vanoglipel, an oral GPR119 agonist for MASH and type 2 diabetes. YUNOVIA, Ildong Pharmaceutical Group’s drug development subsidiary, will present clinical findings on ID110521156, an oral small-molecule GLP-1 receptor agonist, highlighting dose-dependent weight reduction and glycemic control after 28 days.
Long-acting and oral formulations gain traction
Several Korean companies are focusing on once-monthly injectables to reduce treatment burden. Peptron will present data on PT403, a once-monthly semaglutide candidate using sustained-release technology. G2GBIO will showcase preclinical data on one-month subcutaneous formulations for dual and triple agonists, including CagriSema, tirzepatide, and retatrutide, using its InnoLAMP microsphere platform. Inventage Lab will present preclinical findings on IVL3021 (semaglutide-based) and IVL3024 (tirzepatide-based), both leveraging its IVL-DrugFluidic platform. Daewon Pharmaceutical will present preclinical data on a GLP-1/GIP/GCG/gastrin quadruple agonist, co-developed with Pharmus Bioscience, targeting obesity while exploring beta-cell protection and kidney function improvement.
Regulatory and channel signals
ADA 2026, held from Friday to Monday in New Orleans, has expanded its agenda beyond diabetes to include obesity, MASH, cardiovascular disease, and kidney disease, reflecting the growing influence of GLP-1-based therapies. The global obesity drug market is increasingly driven by next-generation therapies that preserve lean mass, improve body composition, and extend benefits to multiple organ systems. Oral GLP-1 drugs and long-acting injectables are gaining interest as alternatives to current injectable-dominated treatments, potentially opening new sourcing opportunities for distributors and clinics.
Sourcing context
For overseas importers and clinic buyers, the Korean pipeline at ADA 2026 highlights a shift toward more sophisticated obesity treatments that address muscle loss and metabolic comorbidities. Companies like Hanmi, Peptron, and Inventage Lab are developing long-acting formulations that could reduce dosing frequency, while YUNOVIA and MetaVia are advancing oral options. These developments may influence future procurement strategies for aesthetic and metabolic health clinics, particularly as the market moves beyond weight-loss efficacy to include body composition and convenience.
Source: Read the original report | Published: June 04, 2026